Pebody R G, Gay N J, Giammanco A, Baron S, Schellekens J, Tischer A, Olander R M, Andrews N J, Edmunds W J, Lecoeur H, Lévy-Bruhl D, Maple P A C, de Melker H, Nardone A, Rota M C, Salmaso S, Conyn-van Spaendonck M A E, Swidsinski S, Miller E
Immunisation Department, Health Protection Agency (HPA) Communicable Disease Surveillance Centre, London, UK.
Epidemiol Infect. 2005 Feb;133(1):159-71. doi: 10.1017/s0950268804003012.
High titres of pertussis toxin (PT) antibody have been shown to be predictive of recent infection with Bordetella pertussis. The seroprevalence of standardized anti-PT antibody was determined in six Western European countries between 1994 and 1998 and related to historical surveillance and vaccine programme data. Standardized anti-PT titres were calculated for a series of whole-cell and acellular pertussis vaccine trials. For the serological surveys, high-titre sera (> 125 units/ml) were distributed throughout all age groups in both high- (> 90%) and low-coverage (< 90%) countries. High-titre sera were more likely in infants in countries using high-titre-producing vaccines in their primary programme (Italy, 11.5%; Western Germany, 13.3%; France, 4.3%; Eastern Germany, 4.0%) compared to other countries (The Netherlands, 0.5%; Finland, 0%). Recent infection was significantly more likely in adolescents (10-19 years old) and adults in high-coverage countries (Finland, The Netherlands, France, East Germany), whereas infection was more likely in children (3-9 years old) than adolescents in low-coverage (< 90%; Italy, West Germany, United Kingdom) countries. The impact and role of programmatic changes introduced after these surveys aimed at protecting infants from severe disease by accelerating the primary schedule or vaccinating older children and adolescents with booster doses can be evaluated with this approach.
高滴度的百日咳毒素(PT)抗体已被证明可预测近期感染百日咳博德特氏菌。1994年至1998年期间,在六个西欧国家测定了标准化抗PT抗体的血清流行率,并将其与历史监测和疫苗计划数据相关联。计算了一系列全细胞和无细胞百日咳疫苗试验的标准化抗PT滴度。对于血清学调查,高滴度血清(>125单位/毫升)在高覆盖率(>90%)和低覆盖率(<90%)国家的所有年龄组中均有分布。与其他国家(荷兰,0.5%;芬兰,0%)相比,在其主要计划中使用产生高滴度疫苗的国家(意大利,11.5%;西德,13.3%;法国,4.3%;东德,4.0%)的婴儿中,高滴度血清更为常见。在高覆盖率国家(芬兰、荷兰、法国、东德)的青少年(10 - 19岁)和成年人中,近期感染的可能性显著更高,而在低覆盖率(<90%;意大利、西德、英国)国家,儿童(3 - 9岁)比青少年更易感染。通过这种方法可以评估这些调查后引入的旨在通过加速初免程序或用加强剂量为大龄儿童和青少年接种疫苗来保护婴儿免受严重疾病影响的计划变更的影响和作用。